<DOC>
	<DOCNO>NCT00960115</DOCNO>
	<brief_summary>This phase I/II study Japan evaluate safety EMD531444 effect survival time patient stage III unresectable non-small cell lung cancer .</brief_summary>
	<brief_title>Study Tecemotide ( L-BLP25 ) Participants With Stage III Unresectable Non-small Cell Lung Cancer ( NSCLC ) Following Primary Chemoradiotherapy</brief_title>
	<detailed_description>Phase I part design evaluate safety EMD531444 930 microgram ( mcg ) dose use phase II . Phase II part design conduct randomize , double blind , placebo control study compare overall survival time randomize subject .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Receipt concomitant sequential chemoradiotherapy , consist minimum two cycle platinumbased chemotherapy minimum radiation dose great equal ( &gt; = ) 50 Gray ( Gy ) . Participant must complete primary thoracic chemoradiotherapy least 4 week later 12 week prior randomization Written inform consent give studyrelated activity carry . Histologically cytologically document unresectable stage III NSCLC . Cancer stage must confirm document Computed Tomography ( CT ) , magnetic resonance imaging ( MRI ) , positron emission tomography ( PET ) scan Documented stable disease objective response , accord RECIST , primary chemoradiotherapy unresectable stage III disease , within four week prior randomization Receipt concomitant sequential chemoradiotherapy , consist minimum two cycle platinumbased chemotherapy minimum radiation dose &gt; = 50 Gy Eastern cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bone marrow function Greater equal 20 year age Lung cancerspecific therapy ( include surgery ) , primary chemoradiotherapy . Note : exploratory surgery study entry allow Immunotherapy ( e.g. , interferon , tumor necrosis factor [ TNF ] , interleukins , biological response modifier [ granulocyte macrophage colony stimulate factor { GMCSF } , granulocyte colony stimulate factor { GCSF } , macrophagecolony stimulate factor { MCSF } ] , monoclonal antibody ) receive within four week prior randomization Malignant pleural/pericardial effusion pleural dissemination separate tumor nodule lobe initial diagnosis and/or study entry Past current history neoplasm lung carcinoma , except adequately treat nonmelanoma skin cancer , situ carcinoma cervix , cancer curatively treat evidence disease least five year Autoimmune disease A recognized immunodeficiency disease include cellular immunodeficiency , hypogammaglobulinemia , dysgammaglobulinemia ; participant hereditary congenital/acquired immunodeficiency Any preexist medical condition require chronic steroid immunosuppressive therapy , include presence diffuse radiation pneumonitis spread involved field Known Hepatitis B and/or C Clinically significant hepatic dysfunction Clinically significant renal dysfunction Clinically significant cardiac disease Splenectomy Infectious process , opinion investigator , could compromise subject 's ability mount immune response Pregnant breastfeeding woman . Participants investigator considers may risk pregnancy pregnancy test perform per institutional standard . Male female subject reproductive ability , unless use effective contraception determine investigator throughout study least 6 month last study treatment Known drug abuse alcohol abuse Legal incapacity limit legal capacity</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Stage III</keyword>
	<keyword>EMD531444</keyword>
	<keyword>L-BLP25</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Tecemotide</keyword>
</DOC>